TAK, US8740602052

Takeda reports psoriasis data: Takeda Pharmaceutical stock sits 3.04 percent below its high

Published on 10/14/2026 at 12:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zasocitinib reached 36.50 percent PASI 100 versus 13.90 percent for the comparator. Takeda Pharmaceutical stock costs EUR 16.60 on October 14, 2026.

Pipeline milestones and reporting dates

Zasocitinib reached 36.50 percent complete skin clearance versus 13.90 percent for the comparator on October 13, 2026.
Takeda will release fiscal 2026 second-quarter results on October 29, 2026.
Takeda Pharmaceutical stock was at EUR 16.60 at 12:29 p.m. CEST at Lang & Schwarz on October 14, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical stock (ISIN US8740602052) was 3.04 percent below its USD 19.10 52-week high while Takeda reported positive Phase 3 psoriasis data on October 13, 2026. Simply Wall St reported that zasocitinib achieved 36.50 percent complete skin clearance at week 16, compared with 13.90 percent for deucravacitinib across the LATITUDE Phase 3 program.

Psoriasis data strengthen the pipeline

The result gives Takeda a quantified late-stage development milestone as regulators review zasocitinib for plaque psoriasis. The comparison was 22.60 percentage points in Takeda's favor, calculated from the reported 36.50 percent and 13.90 percent response rates.

ScanX reported that Takeda's first-quarter fiscal 2026 revenue rose 10.20 percent on an actual foreign exchange basis to JPY 1.22 trillion, while core revenue fell 0.50 percent at constant exchange rates. That split shows how currency helped reported growth while underlying operating momentum remained more restrained.

Three dated pipeline milestones

On July 30, 2026, Takeda reported first-quarter fiscal 2026 core revenue of JPY 1.22 trillion and core earnings per share of JPY 154, according to ScanX. On September 14, 2026, the same source reported that the US Food and Drug Administration accepted the zasocitinib application for priority review, with a first-quarter 2027 action date.

On October 13, 2026, the EADV 2026 readout supplied the latest milestone: 36.50 percent of patients reached complete skin clearance with zasocitinib versus 13.90 percent with deucravacitinib. The numerical gap matters because it links the pipeline story to a defined clinical endpoint rather than to an undated research claim.

What comes next for Takeda

Takeda's investor page schedules the fiscal 2026 second-quarter earnings announcement for October 29, 2026, with an investor webcast from 7:00 p.m. to 8:15 p.m. JST on the same date. The company also plans to present late-stage oncology research, including Phase 3 data, at the ESMO session on October 23, 2026, according to Gekko.

The near-term calendar therefore combines a clinical data event with a scheduled financial checkpoint. The October results will show whether first-quarter revenue growth of 10.20 percent on an actual foreign exchange basis is continuing and whether the 0.50 percent constant-currency core revenue decline is narrowing.

Stock price and market context

Takeda Pharmaceutical stock was trading at EUR 16.60 at Lang & Schwarz on October 14, 2026, at 12:29 p.m. CEST. The primary US listing is NYSE: TAK, and the stock's USD 12.99 to USD 19.10 52-week range and USD 58.9 billion market capitalization were reported for October 13, 2026.

The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.